Skip to main content

Table 2 Univariate and multivariate analyses of PFS

From: Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

Variable (comparator) Progression free survival
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
Early ir-fatigue
 Yes vs no 2.25 (1.63–3.1) < 0.0001 2.29 (1.62–3.22) < 0.0001
Sex
 Male vs female 1.05 (0.78–1.41) 0.7515
Age at diagnosis
 Elderly vs non-elderly 1.20 (0.91–1.58) 0.1940
Primary tumor (melanoma)
 NSCLC 1.51 (1.09–2.08) 0.0124 1.08 (0.76–1.53) 0.6446
 Renal cell carcinoma 1.55 (1.06–2.28) 0.0241 1.22 (0.81–1.85) 0.3445
 Others 1.38 (0.43–4.40) 0.5790 0.95 (0.29–3.06) 0.9336
Treatment line
 Non-first vs first 1.75 (1.28–2.42) 0.0005 1.66 (1.17–2.35) 0.0041